论文部分内容阅读
目的探究匹多莫德口服液联合蒲地兰消炎口服液治疗儿童手足口病的临床疗效。方法选取2014年5月—2016年5月在首都医科大学附属北京同仁医院治疗的手足口病儿童患者84例,随机分为对照组和治疗组,每组各42例。对照组患儿口服蒲地兰消炎口服液,1岁以下5 m L/次,1~3岁6.7 m L/次,3岁以上10 m L/次,3次/d。治疗组患儿在对照组的基础上口服匹多莫德口服液,400 mg/次,2次/d。两组患儿均连续治疗6 d。比较两组患儿临床疗效、总病程时间、体征平均消失时间及治疗前后血常规和血清C反应蛋白(CRP)变化。结果治疗后,对照组和治疗组的总有效率分别为88.10%、97.62%,两组总有效率比较差异有统计学意义(P<0.05)。治疗后,治疗组患者的总病程时间和各种病症消失时间均显著短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者白细胞(WBC)、中性粒细胞(GRAN)、肌酸激酶(CK)和CRP水平均显著接近正常值,同组比较差异具有统计学意义(P<0.05);且治疗后治疗组患者血常规和血清CRP改善程度优于对照组,两组比较差异具有统计学意义(P<0.05)。结论匹多莫德口服液联合蒲地兰消炎口服液对儿童手足口病具有更高的有效率和改善效果,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Pidotimod oral solution combined with Pandilan antiphlogistic oral liquid in the treatment of hand-foot-mouth disease in children. Methods From May 2014 to May 2016, 84 children with hand-foot-mouth disease treated by Beijing Tongren Hospital affiliated to Capital Medical University were randomly divided into control group and treatment group, with 42 cases in each group. Children in the control group were given poyanglan oral solution orally, 5 m L / time under 1 year old, 6.7 m L / 3 years old, 10 m L / 3 years old and 3 times / d. The children in the treatment group were given Pidotimod oral solution 400 mg twice daily on the basis of the control group. Two groups of children were treated for 6 days. The clinical efficacy, duration of the disease, mean disappearance of signs and changes of blood routine and serum C-reactive protein (CRP) before and after treatment were compared between the two groups. Results After treatment, the total effective rates of the control group and the treatment group were 88.10% and 97.62%, respectively. There was significant difference between the two groups in total effective rate (P <0.05). After treatment, the total duration of the course of the treatment group patients and the disappearance of various symptoms were significantly shorter than the control group, the difference between the two groups was statistically significant (P <0.05). After treatment, the levels of WBC, GRAN, CK and CRP were significantly close to normal in both groups, with statistical significance (P <0.05); and treatment The improvement of blood routine and serum CRP in the post-treatment group was better than that in the control group, with significant difference between the two groups (P <0.05). Conclusion Pidotimod oral solution combined with Pandilan antiphlogistic oral liquid on foot and mouth disease in children with higher efficiency and improve the effect of a certain clinical application value.